Compass Therapeutics (CMPX) EBIT (2018 - 2026)
Compass Therapeutics recorded quarterly EBIT of -$20.3 million in Q1 2026, down 12.83% quarter-over-quarter from -$18.0 million in Q4 2025, and down 12.99% year-over-year from -$23.3 million in Q1 2025.
Compass Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$20.3 million for Q1 2026.
- In Q1 2026, EBIT fell 12.99% year-over-year to -$20.3 million; the TTM figure through Mar 2026 stood at -$75.2 million (down 21.59% YoY), while the FY2025 annual figure was -$72.8 million, down 28.63% from the prior year.
- EBIT came in at -$20.3 million for Q1 2026 at Compass Therapeutics, down from -$18.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$7.2 million in Q1 2022 to a low of -$21.1 million in Q2 2025.
- A 5-year average of -$14.2 million and a median of -$13.3 million in 2023 frame the typical range for EBIT.
- Across the five-year window, EBIT slumped 115.2% in 2022 and climbed 5.33% in 2023, its largest moves.
- Compass Therapeutics' EBIT stood at -$12.9 million in 2022, then decreased by 19.44% to -$15.4 million in 2023, then fell by 7.67% to -$16.6 million in 2024, then fell by 8.54% to -$18.0 million in 2025, then fell by 12.83% to -$20.3 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$20.3 million, -$18.0 million, and -$15.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -20.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.30 Mn |
| Dec 31, 2025 | -17.99 Mn |
| Sep 30, 2025 | -15.82 Mn |
| Jun 30, 2025 | -21.07 Mn |
| Mar 31, 2025 | -17.97 Mn |
| Dec 31, 2024 | -16.57 Mn |
| Sep 30, 2024 | -12.24 Mn |
| Jun 30, 2024 | -15.05 Mn |
| Mar 31, 2024 | -12.77 Mn |
| Dec 31, 2023 | -15.39 Mn |
| Sep 30, 2023 | -11.93 Mn |
| Jun 30, 2023 | -13.34 Mn |
| Mar 31, 2023 | -9.71 Mn |
| Dec 31, 2022 | -12.89 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -8.99 Mn |
| Mar 31, 2022 | -7.18 Mn |
| Dec 31, 2021 | -13.00 Mn |
| Sep 30, 2021 | -5.85 Mn |
| Mar 31, 2021 | -7.34 Mn |
| Sep 30, 2020 | -8.96 Mn |
| Jun 30, 2020 | -5.07 Mn |
| Mar 31, 2020 | -5.83 Mn |
| Dec 31, 2019 | -10,238.00 |
| Sep 30, 2019 | -8.38 Mn |
| Jun 30, 2019 | -8.67 Mn |
| Dec 31, 2018 | -9,267.00 |
| Sep 30, 2018 | -7,785.00 |
| Jun 30, 2018 | -7,894.00 |